Cadence gets mixed results for IV pain drug

Cadence Pharmaceuticals is reporting mixed results from two Phase III trials of Acetavance, an intravenous version of acetaminophen. One trial missed its primary endpoint of reducing pain intensity levels over 48 hours. That particular study did, however, meet several secondary endpoints. A second trial of Acetavance met its primary endpoint, demonstrating a statistically significant reduction of fever over six hours compared to a placebo. Investors didn't take kindly to the mixed results, sending Cadence's shares down--plunging 28 percent in pre-market trading.

- see this release from Cadence

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.